{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:00:14Z","timestamp":1792144814720,"version":"4.4.0"},"reference-count":42,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"unspecified","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Gastroenterol"],"accepted":{"date-parts":[[2026,5,7]]},"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Anti-tumour necrosis factor (anti-TNF) immunogenicity remains a major barrier to treatment persistence in inflammatory bowel disease, yet data from Middle Eastern populations are lacking. We characterised immunogenicity rates, predictors and loss of response mechanisms in a real-world cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study included 314 anti-TNF treatment courses (212 infliximab, 102 adalimumab) in 248 patients at a tertiary centre in the United Arab Emirates. Immunogenicity was defined by detectable anti-drug antibodies on a drug-tolerant electrochemiluminescent bridging immunoassay with acid dissociation. Drug levels, predictors and loss of response mechanisms were analysed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Immunogenicity developed in 28.3% (89\/314) of courses over median follow-up of 24.0 months (median time to detection 15.0 months, IQR 8.0\u201336.0). Infliximab and adalimumab had comparable rates (26.9% vs 31.4%; p=0.425). Immunogenicity-mediated failure was the leading cause of discontinuation (48.4%). Pre-event trough levels were significantly lower in immunogenic courses (median 3.0 vs 14.0\u2009mcg\/mL; p&lt;0.001). Exploratory receiver operating characteristic thresholds of 5.3 mcg\/mL for infliximab (area under the curve (AUC) 0.880) and 6.4 mcg\/mL for adalimumab (AUC 0.861) predicted immunogenicity with high discrimination. On shared frailty Cox regression, prior surgery was the strongest predictor (HR 1.85, 95%\u2009CI 0.94 to 3.64; p=0.074). A sensitivity analysis excluding rescued patients strengthened the surgery signal (HR 2.80, 95%\u2009CI 1.41 to 5.56; p=0.003). Subcutaneous infliximab showed lower immunogenicity than intravenous infliximab (new starters 1\/25 (4.0%), switchers 1\/33 (3.0%) vs IV 57\/212 (26.9%)); after propensity score matching on five covariates, the difference remained significant (3.8% vs 18.3%; p=0.013), though a new starters-only analysis did not reach significance (p=0.062).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Immunogenicity patterns in this Middle Eastern cohort are consistent with Western data, supporting pharmacokinetic rather than population-specific determinants. These findings suggest a potential benefit of proactive therapeutic drug monitoring and that subcutaneous infliximab may offer an immunogenic advantage warranting prospective validation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjgast-2026-002347","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T13:10:12Z","timestamp":1782479412000},"page":"e002347","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Anti-TNF immunogenicity in a Middle Eastern inflammatory bowel disease cohort: prevalence, predictors and context-specific drug level thresholds"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-8201-8663","authenticated-orcid":false,"given":"Shaima Wasim","family":"Khan","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Sheikh Shakhbout Medical City, Abu Dhabi, UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noorah","family":"Al Hosani","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Sheikh Shakhbout Medical City, Abu Dhabi, UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thaer Khaleel","family":"Swaid","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Sheikh Shakhbout Medical City, Abu Dhabi, UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazin M","family":"Edan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Sheikh Shakhbout Medical City, Abu Dhabi, UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1673-7792","authenticated-orcid":false,"given":"Mohammed Nabil","family":"Quraishi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Sheikh Shakhbout Medical City, Abu Dhabi, UAE"},{"name":"Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK"},{"name":"College of Medicine and Health Sciences, Khalifa University of Science and Technology, Abu Dhabi, UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"2026062606100828000_13.1.e002347.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32448-0"},{"key":"2026062606100828000_13.1.e002347.2","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"The Lancet"},{"key":"2026062606100828000_13.1.e002347.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050516"},{"key":"2026062606100828000_13.1.e002347.4","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13139"},{"key":"2026062606100828000_13.1.e002347.5","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.10.052"},{"key":"2026062606100828000_13.1.e002347.6","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.cgh.2024.07.033","article-title":"Comparative efficacy of biologics and small molecule in ulcerative colitis: a systematic review and network meta-analysis","volume":"23","author":"Shehab","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026062606100828000_13.1.e002347.7","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/apt.70295","article-title":"Network meta-analysis: comparative efficacy of biologics and small molecules in the induction and maintenance of remission in Crohn\u2019s disease","volume":"62","author":"Shehab","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"2026062606100828000_13.1.e002347.8","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2025-079050","article-title":"Medical management of inflammatory bowel diseases","volume":"391","author":"Hashash","year":"2025","journal-title":"BMJ"},{"key":"2026062606100828000_13.1.e002347.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020888"},{"key":"2026062606100828000_13.1.e002347.10","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2468-1253(19)30012-3","article-title":"Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn\u2019s disease: a prospective, multicentre, cohort study","volume":"4","author":"Kennedy","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026062606100828000_13.1.e002347.11","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S2468-1253(24)00044-X","article-title":"Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn\u2019s disease: 3-year data from the prospective, multicentre PANTS cohort study","volume":"9","author":"Chanchlani","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026062606100828000_13.1.e002347.12","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2025-002034","article-title":"Utilisation and real-world effectiveness of advanced therapies for inflammatory bowel disease in Middle Eastern populations: a systematic review","volume":"12","author":"Quraishi","year":"2025","journal-title":"BMJ Open Gastroenterol"},{"key":"2026062606100828000_13.1.e002347.13","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.cgh.2019.03.037","article-title":"Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases","volume":"17","author":"Papamichael","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026062606100828000_13.1.e002347.14","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.02.031"},{"key":"2026062606100828000_13.1.e002347.15","unstructured":"R Core Team . R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing, 2025."},{"key":"2026062606100828000_13.1.e002347.16","doi-asserted-by":"publisher","DOI":"10.1093\/biostatistics\/kxp050"},{"key":"2026062606100828000_13.1.e002347.17","doi-asserted-by":"crossref","first-page":"82","DOI":"10.4103\/sjg.sjg_245_24","article-title":"Prevalence and clinical implications of anti-drug antibody formation and serum drug levels among patients with IBD receiving anti-TNF therapy: A cross-sectional study","volume":"31","author":"Alghamdi","year":"2025","journal-title":"Saudi Journal of Gastroenterology"},{"key":"2026062606100828000_13.1.e002347.18","doi-asserted-by":"crossref","first-page":"571","DOI":"10.4240\/wjgs.v16.i2.571","article-title":"Is tumor necrosis factor-\u03b1 monoclonal therapy with proactive therapeutic drug monitoring optimized for inflammatory bowel disease? Network meta-analysis","volume":"16","author":"Zheng","year":"2024","journal-title":"World J Gastrointest Surg"},{"key":"2026062606100828000_13.1.e002347.19","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1111\/apt.17313","article-title":"Meta-analysis: The efficacy of therapeutic drug monitoring of anti-TNF-therapy in inflammatory bowel disease","volume":"57","author":"Sethi","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"2026062606100828000_13.1.e002347.20","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14051009","article-title":"Cost-effectiveness of therapeutic drug monitoring of anti-TNF therapy in inflammatory bowel disease: a systematic review","volume":"14","author":"Marquez-Megias","year":"2022","journal-title":"Pharmaceutics"},{"key":"2026062606100828000_13.1.e002347.21","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.07.032"},{"key":"2026062606100828000_13.1.e002347.22","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12869"},{"key":"2026062606100828000_13.1.e002347.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.07.055"},{"key":"2026062606100828000_13.1.e002347.24","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000000279"},{"key":"2026062606100828000_13.1.e002347.25","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.08.035"},{"key":"2026062606100828000_13.1.e002347.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2012.10.019"},{"key":"2026062606100828000_13.1.e002347.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.12.026"},{"key":"2026062606100828000_13.1.e002347.28","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1080\/00365521.2016.1245777","article-title":"Concurrent immunomodulator therapy is associated with higher adalimumab trough levels during scheduled maintenance therapy","volume":"52","author":"Bond","year":"2017","journal-title":"Scand J Gastroenterol"},{"key":"2026062606100828000_13.1.e002347.29","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.jaci.2015.03.013","article-title":"Monoclonal antibodies in excess: a simple way to avoid immunogenicity in patients?","volume":"136","author":"Chaigne","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"2026062606100828000_13.1.e002347.30","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.cgh.2024.07.032","article-title":"Ancestral diversity in pharmacogenomics affects treatment for Hispanic\/Latine populations with inflammatory bowel disease","volume":"23","author":"Ioannou","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026062606100828000_13.1.e002347.31","doi-asserted-by":"crossref","DOI":"10.3748\/wjg.v31.i41.111745","article-title":"HLA-C03:04:01 and HLA-B15:18:01 but not HLA-DQA1*05 associated with anti-tumor necrosis factor antibody formation in Taiwanese inflammatory bowel disease patients","volume":"31","author":"Weng","year":"2025","journal-title":"World J Gastroenterol"},{"key":"2026062606100828000_13.1.e002347.32","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/ecco-jcc\/jjae006","article-title":"Impact of HLA-DQA1*05 genotype in immunogenicity and failure to treatment with tumour necrosis factor-alpha antagonists in inflammatory bowel disease: a systematic review and meta-analysis","volume":"18","author":"Rodr\u00edguez-Alcolado","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026062606100828000_13.1.e002347.33","doi-asserted-by":"crossref","DOI":"10.1007\/s00384-023-04349-1","article-title":"Immunomodulator comedication promotes the reversal of anti-drug antibody-mediated loss of response to anti-TNF therapy in inflammatory bowel disease","volume":"38","author":"Stallhofer","year":"2023","journal-title":"Int J Colorectal Dis"},{"key":"2026062606100828000_13.1.e002347.34","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1097\/MIB.0000000000001043","article-title":"A real-life population pharmacokinetic study reveals factors associated with clearance and immunogenicity of infliximab in inflammatory bowel disease","volume":"23","author":"Brandse","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"2026062606100828000_13.1.e002347.35","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.04.016"},{"key":"2026062606100828000_13.1.e002347.36","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1111\/apt.17170","article-title":"Implications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti-TNF therapy (IMSAT) therapeutic drug monitoring study","volume":"56","author":"Chanchlani","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"2026062606100828000_13.1.e002347.37","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.02.068"},{"key":"2026062606100828000_13.1.e002347.38","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjae127","article-title":"Subcutaneous infliximab cutoff points in patients with inflammatory bowel disease: data from the ENEIDA registry","volume":"19","author":"Iborra","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026062606100828000_13.1.e002347.39","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1053\/j.gastro.2024.05.006","article-title":"Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for inflammatory bowel disease: two randomized phase 3 trials (LIBERTY)","volume":"167","author":"Hanauer","year":"2024","journal-title":"Gastroenterology"},{"key":"2026062606100828000_13.1.e002347.40","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/j.cgh.2022.08.011","article-title":"Effectiveness of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel diseases: the REMSWITCH study","volume":"21","author":"Buisson","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026062606100828000_13.1.e002347.41","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izaf038"},{"key":"2026062606100828000_13.1.e002347.42","doi-asserted-by":"crossref","DOI":"10.1177\/17562848241230902","article-title":"Attitudes, perceptions and barriers in implementing therapeutic drug monitoring for anti-TNFs in inflammatory bowel disease: a survey from the Middle East","volume":"17","author":"Nigam","year":"2024","journal-title":"Ther Adv Gastroenterol"}],"container-title":["BMJ Open Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgast-2026-002347","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T13:10:21Z","timestamp":1782479421000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopengastro.bmj.com\/lookup\/doi\/10.1136\/bmjgast-2026-002347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,6,26]]},"published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1136\/bmjgast-2026-002347"],"URL":"https:\/\/doi.org\/10.1136\/bmjgast-2026-002347","relation":{},"ISSN":["2054-4774"],"issn-type":[{"value":"2054-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]}}}